Manages central diabetes insipidus. ANDA 213095, held by Aurobindo Pharma. Desmopressin Acetate.
As of Nov 16, 2026, ANDA 213095 (Desmopressin Acetate), held by Aurobindo Pharma, was first approved by FDA on Mar 21, 2024, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Central Diabetes Insipidus: Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 21, 2024 | Original application | Approved | None posted |
| Desmopressin Acetate0.1MG · tablet;oral | Desmopressin Acetate | Rx |
| Desmopressin Acetate0.2MG · tablet;oral | Desmopressin Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters